周一，Oppenheimer调整了对Intellia Therapeutics (NASDAQ:NTLA)股票的展望，将公司的目标价从之前的60.00美元下调至40.00美元。尽管目标价下调，但该公司仍维持对这家生物技术公司股票的"优于大市"评级。这一决定是在Intellia Therapeutics宣布战略调整和裁员以延长财务周期后做出的。

NEW YORK CITY, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

智通财经APP获悉，美国基因编辑公司Intellia ...

Oppenheimer lowered the firm’s price target on Intellia Therapeutics (NTLA) to $40 from $60 and keeps an Outperform rating on the shares after ...

（马萨诸塞10日讯）美国基因编辑公司Intellia ...

Wedbush reaffirmed their neutral rating on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a report published ...

周五，BMO Capital Markets调整了对Intellia Therapeutics股票的展望，将目标价从之前的70美元下调至50美元，同时维持"跑赢大市"评级。此次调整是在Intellia Therapeutics分享了其展望2025年的战略计划之后做出的，该计划包括专注于执行ATTR和HAE的III期试验，目标是在2027年前获得HAE的批准。

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Intellia Therapeutics Inc. is shedding employees and paring down its pipeline as it transforms from a late-stage development ...

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...